KR20160146727A - 대사물 패널에 기초하여 혈액 샘플의 품질을 결정하기 위한 수단 및 방법 - Google Patents
대사물 패널에 기초하여 혈액 샘플의 품질을 결정하기 위한 수단 및 방법 Download PDFInfo
- Publication number
- KR20160146727A KR20160146727A KR1020167029433A KR20167029433A KR20160146727A KR 20160146727 A KR20160146727 A KR 20160146727A KR 1020167029433 A KR1020167029433 A KR 1020167029433A KR 20167029433 A KR20167029433 A KR 20167029433A KR 20160146727 A KR20160146727 A KR 20160146727A
- Authority
- KR
- South Korea
- Prior art keywords
- sample
- marker
- value
- quality
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 137
- 210000004369 blood Anatomy 0.000 title claims abstract description 57
- 239000008280 blood Substances 0.000 title claims abstract description 57
- 239000002207 metabolite Substances 0.000 title description 57
- 239000003550 marker Substances 0.000 claims abstract description 125
- 239000010836 blood and blood product Substances 0.000 claims abstract description 86
- 229940125691 blood product Drugs 0.000 claims abstract description 86
- 210000002381 plasma Anatomy 0.000 claims description 116
- 239000000090 biomarker Substances 0.000 claims description 111
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 claims description 58
- 238000012545 processing Methods 0.000 claims description 41
- 238000003860 storage Methods 0.000 claims description 37
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 claims description 34
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 30
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 30
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 30
- 229960003104 ornithine Drugs 0.000 claims description 30
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 claims description 29
- 230000007774 longterm Effects 0.000 claims description 29
- RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical compound OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 claims description 28
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 25
- 238000000926 separation method Methods 0.000 claims description 22
- 238000011156 evaluation Methods 0.000 claims description 20
- 238000013480 data collection Methods 0.000 claims description 19
- 238000004422 calculation algorithm Methods 0.000 claims description 18
- 210000000601 blood cell Anatomy 0.000 claims description 15
- 238000001514 detection method Methods 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 238000013500 data storage Methods 0.000 claims description 14
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 11
- 238000003556 assay Methods 0.000 claims description 10
- 238000007477 logistic regression Methods 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 7
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 6
- 229940009098 aspartate Drugs 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 239000000523 sample Substances 0.000 description 215
- 238000004458 analytical method Methods 0.000 description 64
- 238000004949 mass spectrometry Methods 0.000 description 58
- 150000001875 compounds Chemical class 0.000 description 31
- 238000004811 liquid chromatography Methods 0.000 description 24
- 238000005119 centrifugation Methods 0.000 description 20
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 18
- 239000000126 substance Substances 0.000 description 18
- 238000004817 gas chromatography Methods 0.000 description 17
- 210000002966 serum Anatomy 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 13
- 239000012071 phase Substances 0.000 description 13
- 238000003908 quality control method Methods 0.000 description 13
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 12
- 238000011534 incubation Methods 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 10
- 150000002632 lipids Chemical class 0.000 description 10
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000003146 anticoagulant agent Substances 0.000 description 9
- 229940127219 anticoagulant drug Drugs 0.000 description 9
- 239000011159 matrix material Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 230000005526 G1 to G0 transition Effects 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 238000004590 computer program Methods 0.000 description 7
- 238000001212 derivatisation Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- 239000012620 biological material Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 150000002066 eicosanoids Chemical class 0.000 description 6
- 238000006198 methoxylation reaction Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 206010018910 Haemolysis Diseases 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 238000013401 experimental design Methods 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 229930195712 glutamate Natural products 0.000 description 5
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 5
- 230000008588 hemolysis Effects 0.000 description 5
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- MSPCIZMDDUQPGJ-UHFFFAOYSA-N N-methyl-N-(trimethylsilyl)trifluoroacetamide Chemical compound C[Si](C)(C)N(C)C(=O)C(F)(F)F MSPCIZMDDUQPGJ-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 238000010241 blood sampling Methods 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 150000003943 catecholamines Chemical class 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 238000001303 quality assessment method Methods 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- 238000012772 sequence design Methods 0.000 description 4
- 238000006884 silylation reaction Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 4
- 238000004885 tandem mass spectrometry Methods 0.000 description 4
- 238000006227 trimethylsilylation reaction Methods 0.000 description 4
- 238000004252 FT/ICR mass spectrometry Methods 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 230000003139 buffering effect Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000001095 inductively coupled plasma mass spectrometry Methods 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000007884 metabolite profiling Methods 0.000 description 3
- 238000002705 metabolomic analysis Methods 0.000 description 3
- 230000001431 metabolomic effect Effects 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000005191 phase separation Methods 0.000 description 3
- 238000007781 pre-processing Methods 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000006920 protein precipitation Effects 0.000 description 3
- 238000000575 proteomic method Methods 0.000 description 3
- 238000007637 random forest analysis Methods 0.000 description 3
- 239000013074 reference sample Substances 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 125000005480 straight-chain fatty acid group Chemical group 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 108010026552 Proteome Proteins 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 238000010811 Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry Methods 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000008512 biological response Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 238000013375 chromatographic separation Methods 0.000 description 2
- 238000007635 classification algorithm Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N glycerol 1-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- XNXVOSBNFZWHBV-UHFFFAOYSA-N hydron;o-methylhydroxylamine;chloride Chemical compound Cl.CON XNXVOSBNFZWHBV-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 229960001252 methamphetamine Drugs 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000000009 pyrolysis mass spectrometry Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000002098 selective ion monitoring Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000002553 single reaction monitoring Methods 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 150000003408 sphingolipids Chemical group 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000002366 time-of-flight method Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- IHCCLXNEEPMSIO-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 IHCCLXNEEPMSIO-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000033962 Fontaine progeroid syndrome Diseases 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241001069925 Orestes Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000009932 biopreservation Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003130 blood coagulation factor inhibitor Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000000738 capillary electrophoresis-mass spectrometry Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000002790 cross-validation Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000013079 data visualisation Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000000835 electrochemical detection Methods 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000005183 environmental health Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000011152 fibreglass Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000002546 full scan Methods 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000752 ionisation method Methods 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000007620 mathematical function Methods 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000009120 phenotypic response Effects 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000005173 quadrupole mass spectroscopy Methods 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 238000013441 quality evaluation Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000010833 quantitative mass spectrometry Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000012284 sample analysis method Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010845 search algorithm Methods 0.000 description 1
- 238000012764 semi-quantitative analysis Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- -1 small molecule compound Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 150000003410 sphingosines Chemical class 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 238000012706 support-vector machine Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/492—Determining multiple analytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
- G16B50/30—Data warehousing; Computing architectures
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2496/00—Reference solutions for assays of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Theoretical Computer Science (AREA)
- Biophysics (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Databases & Information Systems (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioethics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Evolutionary Biology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Ecology (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Public Health (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14161766 | 2014-03-26 | ||
| EP14161766.2 | 2014-03-26 | ||
| PCT/IB2015/052243 WO2015145387A1 (en) | 2014-03-26 | 2015-03-26 | Means and methods for determination of quality of blood samples based on metabolite panel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20160146727A true KR20160146727A (ko) | 2016-12-21 |
Family
ID=50433941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020167029433A Withdrawn KR20160146727A (ko) | 2014-03-26 | 2015-03-26 | 대사물 패널에 기초하여 혈액 샘플의 품질을 결정하기 위한 수단 및 방법 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20180217125A1 (enExample) |
| EP (1) | EP3123174A4 (enExample) |
| JP (1) | JP2017512996A (enExample) |
| KR (1) | KR20160146727A (enExample) |
| CN (1) | CN106415274A (enExample) |
| AU (1) | AU2015237804A1 (enExample) |
| BR (1) | BR112016021929A2 (enExample) |
| CA (1) | CA2941979A1 (enExample) |
| WO (1) | WO2015145387A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108369612A (zh) * | 2015-11-04 | 2018-08-03 | 梅塔博隆股份有限公司 | 自动化样品质量评估 |
| EP3628068A4 (en) * | 2017-05-02 | 2020-12-30 | Liquid Biosciences, Inc. | SYSTEMS AND METHODS FOR DETERMINING THE ATTRIBUTES OF BIOLOGICAL SAMPLES |
| US20200182862A1 (en) * | 2017-06-16 | 2020-06-11 | DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH | Method and apparatus for single tube blood donor screening |
| CN107818329B (zh) * | 2017-08-09 | 2023-04-18 | 亿纳谱（浙江）生物科技有限公司 | 一种质谱数据分析方法 |
| CN107782825A (zh) * | 2017-12-01 | 2018-03-09 | 武汉迈特维尔生物科技有限公司 | 一种基于液相色谱检测动物体中小分子代谢物的方法 |
| CN110609139B (zh) * | 2018-06-14 | 2023-06-30 | 深圳市理邦精密仪器股份有限公司 | 抗原浓度过量检测方法、装置及存储介质 |
| WO2020225946A1 (ja) * | 2019-05-09 | 2020-11-12 | 株式会社島津製作所 | 試料の評価方法、分析方法、劣化試料の検出方法、劣化血漿試料検出用マーカーおよび劣化血清試料検出用マーカー |
| US20210087603A1 (en) * | 2019-09-20 | 2021-03-25 | Charite - Universitaetsmedizin Berlin | Methods, kits and devices for measuring extracellular pyridine nucleotide |
| CN110890130B (zh) * | 2019-12-03 | 2022-09-20 | 大连理工大学 | 基于多类型关系的生物网络模块标志物识别方法 |
| CN111239283A (zh) * | 2020-02-18 | 2020-06-05 | 深圳脉图精准技术有限公司 | 焦谷氨酸作为判断代谢组学血液样本质量的质检指示物的应用 |
| CN116249904A (zh) * | 2020-07-09 | 2023-06-09 | 赫尔辛基大学 | 用于测定来自样品的nad代谢物的量的方法以及与其相关的方法和用途 |
| JP7600875B2 (ja) * | 2021-06-01 | 2024-12-17 | 株式会社島津製作所 | 試料分析装置、試料分析方法、医薬分析装置および医薬分析方法 |
| WO2023022132A1 (ja) * | 2021-08-17 | 2023-02-23 | 国立研究開発法人理化学研究所 | 成分分析装置および成分分析方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008033575A2 (en) * | 2006-09-15 | 2008-03-20 | Metabolon, Inc. | Methods of identifying biochemical pathways |
| CA2728379C (en) * | 2009-03-04 | 2016-06-14 | John Wan | Collection and assay device for biological fluid |
| PL2438445T3 (pl) * | 2009-06-04 | 2014-12-31 | Metanomics Health Gmbh | Sposoby diagnozowania raków gruczołu krokowego |
| EP2336784B1 (en) * | 2009-12-18 | 2017-08-16 | Roche Diagnostics GmbH | GDF-15 and/or Troponin T for predicting kidney failure in heart surgery patients |
| CN105120852A (zh) * | 2013-02-14 | 2015-12-02 | 梅坦诺米克斯保健有限公司 | 评估生物样品质量的工具和方法 |
| CN103512972A (zh) * | 2013-07-29 | 2014-01-15 | 上海交通大学 | 精神分裂症的生物标志物及其使用方法和应用 |
| AU2014368412A1 (en) * | 2013-12-20 | 2016-07-07 | Metanomics Health Gmbh | Means and methods for diagnosing pancreatic cancer in a subject based on a metabolite panel |
-
2015
- 2015-03-26 BR BR112016021929A patent/BR112016021929A2/pt not_active Application Discontinuation
- 2015-03-26 CA CA2941979A patent/CA2941979A1/en not_active Abandoned
- 2015-03-26 AU AU2015237804A patent/AU2015237804A1/en not_active Abandoned
- 2015-03-26 JP JP2016558687A patent/JP2017512996A/ja active Pending
- 2015-03-26 US US15/128,523 patent/US20180217125A1/en not_active Abandoned
- 2015-03-26 WO PCT/IB2015/052243 patent/WO2015145387A1/en not_active Ceased
- 2015-03-26 CN CN201580027673.9A patent/CN106415274A/zh active Pending
- 2015-03-26 KR KR1020167029433A patent/KR20160146727A/ko not_active Withdrawn
- 2015-03-26 EP EP15768554.6A patent/EP3123174A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015237804A1 (en) | 2016-09-22 |
| EP3123174A1 (en) | 2017-02-01 |
| EP3123174A4 (en) | 2017-12-06 |
| CA2941979A1 (en) | 2015-10-01 |
| CN106415274A (zh) | 2017-02-15 |
| BR112016021929A2 (pt) | 2017-08-15 |
| JP2017512996A (ja) | 2017-05-25 |
| WO2015145387A1 (en) | 2015-10-01 |
| US20180217125A1 (en) | 2018-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20160146727A (ko) | 대사물 패널에 기초하여 혈액 샘플의 품질을 결정하기 위한 수단 및 방법 | |
| Picotti et al. | Selected reaction monitoring–based proteomics: workflows, potential, pitfalls and future directions | |
| Veenstra | Global and targeted quantitative proteomics for biomarker discovery | |
| Baker et al. | Mass spectrometry for translational proteomics: progress and clinical implications | |
| JP6388606B2 (ja) | 生物学的サンプルの質を評価するための手段及び方法 | |
| US8389222B2 (en) | Apolipoprotein fingerprinting technique and methods related thereto | |
| CN101443663A (zh) | 诊断糖尿病的工具和方法 | |
| BRPI0711967A2 (pt) | ensaio de biomarcador de espectrometria de massa | |
| Plubell et al. | Development of highly multiplex targeted proteomics assays in biofluids using the Stellar mass spectrometer | |
| WO2008022266A2 (en) | Methods and systems for quantifying isobaric labels and peptides | |
| Velstra et al. | Detection of pancreatic cancer using serum protein profiling | |
| Lardinois et al. | Mass spectrometric analysis of rat cerebrospinal fluid proteins following exposure to the neurotoxicant carbonyl sulfide | |
| Kiseleva et al. | Plasma preparation to measure FDA-approved protein markers by selected reaction monitoring | |
| Letunica et al. | Proteomic applications and considerations: from research to patient care | |
| US20170220737A1 (en) | Means and Methods for Assessing a Quality of a Biological Sample | |
| Díez et al. | Genomics and proteomics for biomarker validation | |
| JP2019039915A (ja) | 生物学的サンプルの質を評価するための手段及び方法 | |
| Di Tommaso et al. | Quantitative enrichment of amyloid precursors refines mass spectrometry-based amyloidosis diagnosis | |
| JPWO2023039579A5 (enExample) | ||
| Hincapie et al. | Multi-lectin Affinity Chromatography (M-LAC) Combined with Abundant Protein Depletion for Analysis of Human Plasma in Clinical Proteomics Applications | |
| Pavlou et al. | Discovery and Validation Case Studies, Recommendations: Bottlenecks in Biomarker Discovery and Validation by Using Proteomic Technologies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20161021 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination |